Streetbeat News

Analyst Ratings

BURL

Gordon Haskett analyst Chuck Grom upgrades Burlington Stores (NYSE:BURL) from Accumulate to Buy and lowers the price target from $200 to $175.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:30 am

ACCD

Needham analyst Ryan MacDonald has reiterated a Buy rating on Accolade (NASDAQ:ACCD) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:27 am

BMEA

HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Biomea Fusion (NASDAQ:BMEA) and raises the price target from $37 to $50.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:20 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:19 am

ASLN

HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a $17 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:18 am

RVPH

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:17 am

IONQ

Needham analyst Quinn Bolton maintains a Buy rating on IonQ (NYSE:IONQ) and raises the price target from $9 to $11.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:17 am

ESPR

HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:15 am

VRTX

HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $380 price target.

Portfolio Pulse from richadhand@benzinga.com

June 26, 2023 | 10:13 am